Nicotinic acid adenine dinucleotide phosphate-mediated calcium signalling in effector T cells regulates autoimmunity of the central nervous system

Brain

Volumn 133, Issue 7, 2010, Pages 1930-1943

  Cordiglieri, Chiara ^a,g   Odoardi, Francesca ^a,b,c   Zhang, Bo ^d   Nebel, Merle ^e   Kawakami, Naoto ^a   Klinkert, Wolfgang E F ^a   Lodygin, Dimtri ^b   Lühder, Fred ^b   Breunig, Esther ^f   Schild, Detlev ^f   Ulaganathan, Vijay Kumar ^a   Dornmair, Klaus ^a,c   Dammermann, Werner ^e   Potter, Barry V L ^d   Guse, Andreas H ^e   Flügel, Alexander ^a,b,c  

^a MAX PLANCK INSTITUTE OF NEUROBIOLOGY   (Germany)

^b Gemeinnutzige Hertie Stiftung   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d University of Bath   (United Kingdom)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f UNIVERSITY OF GÖTTINGEN   (Germany)

^g DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

experimental autoimmune encephalomyelitis; intravital imaging; multiple sclerosis; nicotinic acid adenine dinucleotide phosphate; T cell signalling

Indexed keywords

BZ 194; GAMMA INTERFERON; INTERLEUKIN 17; NICOTINIC ACID ADENINE DINUCLEOTIDE PHOSPHATE; NICOTINIC ACID DERIVATIVE; RYANODINE RECEPTOR 1; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; CALCIUM SIGNALING; CELL MOTILITY; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; EFFECTOR CELL; IN VITRO STUDY; IN VIVO STUDY; MEMORY T LYMPHOCYTE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; RAT; T LYMPHOCYTE ACTIVATION;

ANIMALS; CALCIUM SIGNALING; CELLS, CULTURED; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; NADP; NICOTINIC ACIDS; RATS; RATS, INBRED LEW; T-LYMPHOCYTE SUBSETS;

EID: 77954382081     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awq135     Document Type: Article

References (42)

1. Aharoni R, Teitelbaum D, Sela M, Arnon R. Copolymer 1 induces T cells of the T helper type 2 that cross-react with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 1997; 94: 10821-10826
2. Bartholomäus I, Kawakami N, Odoardi F, Schlä ger C, Miljkovic D, Ellwart JW, et al. Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions. Nature 2009; 462: 94-98
3. Becher B, Bechmann I, Greter M. Antigen presentation in autoimmunity and CNS inflammation: how T lymphocytes recognize the brain. J Mol Med 2006; 84: 532-543
4. + channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc Natl Acad Sci USA 2001; 98: 13942-13947
5. Beeton C, Wulff H, Standifer NE, Azam P, Mullen KM, Pennington MW, et al. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci USA 2006; 103: 17414-17419
6. Ben-Nun A, Wekerle H, Cohen IR. The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur J Immunol 1981; 11: 195-199
7. Berg I, Potter BVL, Mayr GW, Guse AH. Nicotinic acid adenine dinucleo-tide phosphate (NAADP(+)) is an essential regulator of T-lymphocyte Ca(2+)-signaling. J Cell Biol 2000; 150: 581-588
8. Bhakta NR, Oh DY, Lewis RS. Calcium oscillations regulate thymocyte motility during positive selection in the three-dimensional thymic environment. Nat Immunol 2005; 6: 143-151
9. Bittner S, Meuth SG, Gö bel K, Melzer N, Herrmann AM, Simon OJ, et al. TASK1 modulates inflammation and neurodegeneration in autoimmune inflammation of the central nervous system. Brain 2009; 132: 2501-2516
10. 2+ signaling via type 1 rya-nodine receptor in T cells revealed by a synthetic NAADP antagonist. Proc Natl Acad Sci USA 2009; 106: 10678-10683
11. Feske S, Gwack Y, Prakriya M, Srikanth S, Puppel SH, Tanasa B, et al. A mutation in Orai1 causes immune deficiency by abrogating CRAC channel function. Nature 2006; 441: 179-185
12. Flü gel A, Berkowicz T, Ritter T, Labeur M, Jenne D, Li Z, et al. Migratory activity and functional changes of green fluorescent effector T cells before and during experimental autoimmune encephalomyelitis. Immunity 2001; 14: 547-560
13. + T lymphocytes: green fluorescent protein engineered, encephalitogenic T cells used to illuminate immune responses in the brain. Nature Med 1999; 5: 843-847
14. Fontoura P, Garren H, Steinman L. Antigen-specific therapies in multiple sclerosis: going beyond proteins and peptides. Int Rev Immunol 2005; 24: 415-446
15. Gasser A, Bruhn S, Guse AH. Second messenger function of nicotinic acid adenine dinucleotide phosphate revealed by an improved enzymatic cycling assay. J Biol Chem 2006; 281: 16906-16913
16. Guse AH, da Silva CP, Berg I, Skapenko AL, Weber K, Heyer P, et al. Regulation of calcium signalling in T lymphocytes by the second messenger cyclic ADP-ribose. Nature 1999; 398: 70-73
17. Guse AH, Goldwich A, Weber K, Mayr GW. Non-radioactive, isomer-specific inositol phosphate mass determinations: high-performance liquid chromatography-micro-metal-dye detection strongly improves speed and sensitivity of analyses from cells and micro-enzyme assays. J Chromatogr B Biomed Appl 1995; 672: 189-198
18. Hartung H-P, Heininger K, Schäfer B, Fierz W, Toyka KV. Immune mechanisms in inflammatory neuropathy. Ann NY Acad Sci 1988; 540: 122-161
19. Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006; 355: 1124-1140
20. Kawakami N, Lassmann S, Li Z, Odoardi F, Ritter T, Ziemssen T, et al. The activation status of neuroantigen-specific T cells in the target organ determines the clinical outcome of autoimmune encephalomye-litis. J Exp Med 2004; 199: 185-197
21. Kawakami N, Nägerl UV, Odoardi F, Bonhoeffer T, Wekerle H, Flü gel A. Live imaging of effector cell trafficking and autoantigen recognition within the unfolding autoimmune encephalomyelitis lesion. J Exp Med 2005a; 201: 1805-1814
22. + T cell memory: Lifelong persistence of ence-phalitogenic T cell clones in healthy immune repertoires. J Immunol 2005b; 175: 69-81.
23. Kivisäkk P, Imitola J, Rasmussen S, Elyaman W, Zhu B, Ransohoff RM, et al. Localizing central nervous system immune surveillance: menin-geal antigen-presenting cells activate T cells during experimental autoimmune encephalomyelitis. Ann Neurol 2009; 65: 457-469
24. Langer-Gould A, Steinman L. Progressive multifocal leukoencephalopathy and multiple sclerosis: lessons from natalizumab. Curr Neurol Neurosci Rep 2006; 6: 253-258
25. 2+ signaling in T-lymphocytes. Cell Signal 2004; 16: 1283-1289
26. Markowitz CE. Interferon-beta: mechanism of action and dosing issues. Neurol 2007; 68: S8-11.
27. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, et al. A controlled trial of Natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348: 15-23.
28. Odoardi F, Kawakami N, Klinkert WE, Wekerle H, Flü gel A. Blood-borne soluble protein antigen intensifies T cell activation in autoimmune CNS lesions and exacerbates clinical disease. Proc Natl Acad Sci USA 2007a; 104: 18625-18630
29. Odoardi F, Kawakami N, Li Z, Cordiglieri C, Streyl K, Nosov M, et al. Instant effect of soluble antigen on effector T cells in peripheral immune organs during immunotherapy of autoimmune encephalo-myelitis. Proc Natl Acad Sci USA 2007b; 104: 920-925
30. Peinelt C, Vig M, Koomoa DL, Beck A, Nadler MJ, Koblan-Huberson M, et al. Amplification of CRAC current by STIM1 and CRACM1 (Orai1). Nat Cell Biol 2006; 8: 771-773
31. Powrie F, Mason D. Phenotypic and functional heterogeneity of CD4+ T cells. Immunol Today 1988; 9: 274-277
32. + T lymphocytes differ on CD45RC expression. J Immunol 2000; 165: 1816-1823
33. Safford M, Collins S, Lutz MA, Allen A, Huang CT, Kowalski J, et al. Egr-2 and Egr-3 are negative regulators of T cell activation. Nat Immunol 2005; 6: 472-480
34. Skokos D, Shakhar G, Varma R, Waite JC, Cameron TO, Lindquist RL, et al. Peptide-MHC potency governs dynamic interactions between T cells and dendritic cells in lymph nodes. Nat Immunol 2007; 8: 835-844
35. Steinman L, Waisman A, Altmann D. Major T cell responses in multiple sclerosis. Mol Med Today 1995; 1: 79-83.
36. 2+ from a non-mitochondrial intracellular store in pancreatic acinar cells by inositol-1,4,5-trisphosphate. Nature 1983; 306: 67-69
37. 2+ signals and immunosup-pression. Nature 1996; 383: 837-840
38. Tran EH, Hoekstra K, Van Rooijen N, Dijkstra CD, Owens T. Immune invasion of the central nervous system parenchyma and experimental allergic encephalomyelitis, but not leukocyte extravasation from blood, are prevented in macrophage depleted mice. J Immunol 1998; 161: 3767-3775
39. 2+ entry. Science 2006; 312: 1220-1223
40. Weiner HL. Immunosuppressive treatment in multiple sclerosis. J Neurol Sci 2004; 223: 1-11.
41. Wekerle H, Kojima K, Lannes-Vieira J, Lassmann H, Linington C. Animal models. Ann Neurol 1994; 36: S47-53.
42. Yeromin AV, Zhang SL, Jiang W, Yu Y, Safrina O, Cahalan MD. Molecular identification of the CRAC channel by altered ion selectivity in a mutant of Orai. Nature 2006; 443: 226-229